Zonisamide

唑尼沙胺

Report date: 2026/04/22 20:01:10
NMEFirst In Class

Base Information

Drug NameZonisamide
Drug Alias Name唑尼沙氨Kinaplase唑利磺胺ZonisamidaZonisamidum +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium channel alpha subunit blockersVoltage-gated calcium channel blockersCarbonic anhydrases inhibitors
TargetsCarbonic anhydrasesSodium channel alpha subunitVoltage-gated calcium channel
Therapy Area/IndicationsStress Disorders, Post-TraumaticBipolar DisorderAlcoholism +[13] 
Global Approved IndicationsSeizuresEpilepsies, PartialEpilepsy
Approved Indications in ChinaEpilepsy
Original Approved Country/TerritoryJapan
Original Approved Date1989/03/31
Country/TerritoryCzechiaUnited StatesUkraine +[19] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSumitomo Dainippon Pharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSumitomo DainipponWashington State UniversityBoston University Charles River Campus +[6] 
Inactive CompaniesElan PharmaceuticalsMylan Pharmaceuticals IncWashington University School Of Medicine +[12] 
Active IndicationsAlcoholismSeizuresEpilepsies, Partial +[4] 
Inactive IndicationsStress Disorders, Post-TraumaticBipolar DisorderObesity +[9] 

Other Information

ATC CodeN03AX15
Related LinksWikipediaDrugBankKEGG